Sifting through countless of stocks in the Health Care Equipment & Supplies industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Tandem Diabetes Care, Inc., RxSight or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Tandem Diabetes Care, Inc., RxSight and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Tandem Diabetes Care, Inc., RxSight and Inc.

Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. It’s flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. The company also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user’s body. In addition, it offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. RxSight, Inc. was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. The company was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Latest Health Care Equipment & Supplies and Tandem Diabetes Care, Inc., RxSight, Inc. Stock News

As of July 31, 2026, Tandem Diabetes Care, Inc. had a $1.3 billion market capitalization, compared to the Health Care Equipment & Supplies median of $337.2 million. Tandem Diabetes Care, Inc.’s stock is down 11.3% in 2026, up 13.9% in the previous five trading days and up 17.04% in the past year.

Currently, Tandem Diabetes Care, Inc. does not have a price-earnings ratio. Tandem Diabetes Care, Inc.’s trailing 12-month revenue is $1.0 billion with a -9.2% net profit margin. Year-over-year quarterly sales growth most recently was 5.5%. Analysts expect adjusted earnings to reach $-0.685 per share for the current fiscal year. Tandem Diabetes Care, Inc. does not currently pay a dividend.

As of July 31, 2026, RxSight, Inc. had a $249.4 million market cap, putting it in the 30th percentile of all stocks. RxSight, Inc.’s stock is down 42.3% in 2026, up 15.8% in the previous five trading days and down 24.5% in the past year.

Currently, RxSight, Inc. does not have a price-earnings ratio. RxSight, Inc.’s trailing 12-month revenue is $127.5 million with a -36.6% net profit margin. Year-over-year quarterly sales growth most recently was -18.5%. Analysts expect adjusted earnings to reach $-0.668 per share for the current fiscal year. RxSight, Inc. does not currently pay a dividend.

How We Compare Tandem Diabetes Care, Inc., RxSight and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Tandem Diabetes Care, Inc., RxSight and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Tandem Diabetes Care, Inc., RxSight and Inc. Growth Grades

Company	Ticker	Growth
Tandem Diabetes Care, Inc.	TNDM	C
RxSight, Inc.	RXST	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Tandem Diabetes Care, Inc. has a Growth Score of 45, which is Average. RxSight, Inc. has a Growth Score of 18, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Tandem Diabetes Care, Inc., RxSight or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Tandem Diabetes Care, Inc., RxSight or Inc. is the better investment when it comes to sustainable growth.

Tandem Diabetes Care, Inc., RxSight and Inc.’s Quality Grades

Company	Ticker	Quality
Tandem Diabetes Care, Inc.	TNDM	C
RxSight, Inc.	RXST	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Tandem Diabetes Care, Inc. has a Quality Score of 44, which is Average. RxSight, Inc. has a Quality Score of 56, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Tandem Diabetes Care, Inc., RxSight or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Tandem Diabetes Care, Inc., RxSight or Inc. is the better investment when it comes to quality.

Tandem Diabetes Care, Inc., RxSight and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Tandem Diabetes Care, Inc.	TNDM	B
RxSight, Inc.	RXST	C

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Tandem Diabetes Care, Inc. has a Earnings Estimate Score of 70, which is Positive. RxSight, Inc. has a Earnings Estimate Score of 48, which is Neutral.

The Earnings Estimate Revisions Grade Winner: Tandem Diabetes Care, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Tandem Diabetes Care, Inc. has a better Earnings Estimate Revisions Grade than RxSight, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Tandem Diabetes Care, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Tandem Diabetes Care, Inc., RxSight and Inc. Grades

In addition to Estimate Revisions, Growth and Quality, A+ Investor also provides grades for Value and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection. Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Tandem Diabetes Care, Inc., RxSight and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Tandem Diabetes Care, Inc., RxSight or Inc. Stock?

Overall, Tandem Diabetes Care, Inc. stock has a Growth Score of 45, Estimate Revisions Score of 70 and Quality Score of 44.

RxSight, Inc. stock has a Growth Score of 18, Estimate Revisions Score of 48 and Quality Score of 56.

Comparing Tandem Diabetes Care, Inc., RxSight and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.